Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

34 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
RAS as a positive predictive biomarker: focus on lung and colorectal cancer patients.
Malapelle U, Passiglia F, Cremolini C, Reale ML, Pepe F, Pisapia P, Avallone A, Cortinovis D, De Stefano A, Fassan M, Fontanini G, Galetta D, Lauricella C, Listì A, Loupakis F, Pagni F, Pietrantonio F, Pilotto S, Righi L, Bianchi AS, Parra HS, Tiseo M, Verzè M, Troncone G, Novello S. Malapelle U, et al. Among authors: lauricella c. Eur J Cancer. 2021 Mar;146:74-83. doi: 10.1016/j.ejca.2021.01.015. Epub 2021 Feb 12. Eur J Cancer. 2021. PMID: 33588147 Review.
KRAS gene amplification in colorectal cancer and impact on response to EGFR-targeted therapy.
Valtorta E, Misale S, Sartore-Bianchi A, Nagtegaal ID, Paraf F, Lauricella C, Dimartino V, Hobor S, Jacobs B, Ercolani C, Lamba S, Scala E, Veronese S, Laurent-Puig P, Siena S, Tejpar S, Mottolese M, Punt CJ, Gambacorta M, Bardelli A, Di Nicolantonio F. Valtorta E, et al. Among authors: lauricella c. Int J Cancer. 2013 Sep 1;133(5):1259-65. doi: 10.1002/ijc.28106. Epub 2013 Mar 16. Int J Cancer. 2013. PMID: 23404247 Free article.
Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients.
Siravegna G, Mussolin B, Buscarino M, Corti G, Cassingena A, Crisafulli G, Ponzetti A, Cremolini C, Amatu A, Lauricella C, Lamba S, Hobor S, Avallone A, Valtorta E, Rospo G, Medico E, Motta V, Antoniotti C, Tatangelo F, Bellosillo B, Veronese S, Budillon A, Montagut C, Racca P, Marsoni S, Falcone A, Corcoran RB, Di Nicolantonio F, Loupakis F, Siena S, Sartore-Bianchi A, Bardelli A. Siravegna G, et al. Among authors: lauricella c. Nat Med. 2015 Jul;21(7):795-801. doi: 10.1038/nm.3870. Epub 2015 Jun 1. Nat Med. 2015. PMID: 26030179 Free PMC article.
BRAF codons 594 and 596 mutations identify a new molecular subtype of metastatic colorectal cancer at favorable prognosis.
Cremolini C, Di Bartolomeo M, Amatu A, Antoniotti C, Moretto R, Berenato R, Perrone F, Tamborini E, Aprile G, Lonardi S, Sartore-Bianchi A, Fontanini G, Milione M, Lauricella C, Siena S, Falcone A, de Braud F, Loupakis F, Pietrantonio F. Cremolini C, et al. Among authors: lauricella c. Ann Oncol. 2015 Oct;26(10):2092-7. doi: 10.1093/annonc/mdv290. Epub 2015 Jul 7. Ann Oncol. 2015. PMID: 26153495 Free article.
Value of KRAS as prognostic or predictive marker in NSCLC: results from the TAILOR trial.
Rulli E, Marabese M, Torri V, Farina G, Veronese S, Bettini A, Longo F, Moscetti L, Ganzinelli M, Lauricella C, Copreni E, Labianca R, Martelli O, Marsoni S, Broggini M, Garassino MC; TAILOR trialists. Rulli E, et al. Among authors: lauricella c. Ann Oncol. 2015 Oct;26(10):2079-84. doi: 10.1093/annonc/mdv318. Epub 2015 Jul 24. Ann Oncol. 2015. PMID: 26209642 Free article. Clinical Trial.
KRAS mutations affect prognosis of non-small-cell lung cancer patients treated with first-line platinum containing chemotherapy.
Marabese M, Ganzinelli M, Garassino MC, Shepherd FA, Piva S, Caiola E, Macerelli M, Bettini A, Lauricella C, Floriani I, Farina G, Longo F, Bonomi L, Fabbri MA, Veronese S, Marsoni S, Broggini M, Rulli E. Marabese M, et al. Among authors: lauricella c. Oncotarget. 2015 Oct 20;6(32):34014-22. doi: 10.18632/oncotarget.5607. Oncotarget. 2015. PMID: 26416458 Free PMC article. Clinical Trial.
Assessment of a HER2 scoring system for colorectal cancer: results from a validation study.
Valtorta E, Martino C, Sartore-Bianchi A, Penaullt-Llorca F, Viale G, Risio M, Rugge M, Grigioni W, Bencardino K, Lonardi S, Zagonel V, Leone F, Noe J, Ciardiello F, Pinto C, Labianca R, Mosconi S, Graiff C, Aprile G, Frau B, Garufi C, Loupakis F, Racca P, Tonini G, Lauricella C, Veronese S, Truini M, Siena S, Marsoni S, Gambacorta M. Valtorta E, et al. Among authors: lauricella c. Mod Pathol. 2015 Nov;28(11):1481-91. doi: 10.1038/modpathol.2015.98. Epub 2015 Oct 9. Mod Pathol. 2015. PMID: 26449765 Free article. Clinical Trial.
Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial.
Sartore-Bianchi A, Trusolino L, Martino C, Bencardino K, Lonardi S, Bergamo F, Zagonel V, Leone F, Depetris I, Martinelli E, Troiani T, Ciardiello F, Racca P, Bertotti A, Siravegna G, Torri V, Amatu A, Ghezzi S, Marrapese G, Palmeri L, Valtorta E, Cassingena A, Lauricella C, Vanzulli A, Regge D, Veronese S, Comoglio PM, Bardelli A, Marsoni S, Siena S. Sartore-Bianchi A, et al. Among authors: lauricella c. Lancet Oncol. 2016 Jun;17(6):738-746. doi: 10.1016/S1470-2045(16)00150-9. Epub 2016 Apr 20. Lancet Oncol. 2016. PMID: 27108243 Free article. Clinical Trial.
Pooled Analysis of Clinical Outcome of Patients with Chemorefractory Metastatic Colorectal Cancer Treated within Phase I/II Clinical Studies Based on Individual Biomarkers of Susceptibility: A Single-Institution Experience.
Sartore-Bianchi A, Amatu A, Bonazzina E, Stabile S, Giannetta L, Cerea G, Schiavetto I, Bencardino K, Funaioli C, Ricotta R, Cipani T, Schirru M, Gambi V, Palmeri L, Carlo-Stella G, Rusconi F, Di Bella S, Burrafato G, Cassingena A, Valtorta E, Lauricella C, Pazzi F, Gambaro A, Ghezzi S, Marrapese G, Tarenzi E, Veronese S, Truini M, Vanzulli A, Siena S. Sartore-Bianchi A, et al. Among authors: lauricella c. Target Oncol. 2017 Aug;12(4):525-533. doi: 10.1007/s11523-017-0505-6. Target Oncol. 2017. PMID: 28669023 Free PMC article. Clinical Trial.
Biphenotypic lung carcinoma with coexpression of TTF-1 and ΔNP63/P40 within most of the same individual cells: a further case confirming poor prognosis and a review of literature.
Marando A, Zagni M, Negrelli M, Valtorta E, Lauricella C, Motta V, Veronese S, Cerea G, Giannetta LG, Ciarlo G, Signorelli D, Pizzutilo EG, Bonoldi E, Pelosi G. Marando A, et al. Among authors: lauricella c. Pathologica. 2024 Feb;116(1):13-21. doi: 10.32074/1591-951X-957. Pathologica. 2024. PMID: 38482671 Free PMC article. Review.
34 results